Neurogene Inc. Files 8-K on Operations and Financials

Ticker: NGNE · Form: 8-K · Filed: May 10, 2024 · CIK: 1404644

Sentiment: neutral

Topics: operations, financials, filing

TL;DR

Neurogene Inc. dropped an 8-K detailing its financials and operations.

AI Summary

Neurogene Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., is based in New York, NY.

Why It Matters

This filing provides an update on Neurogene Inc.'s operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing reporting on financial condition and operations, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Neurogene Inc.?

The primary purpose of this 8-K filing is to report on Neurogene Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.

When was this 8-K report filed?

This 8-K report was filed on May 10, 2024.

What was Neurogene Inc.'s former company name?

Neurogene Inc.'s former company name was Neoleukin Therapeutics, Inc.

Where are Neurogene Inc.'s principal executive offices located?

Neurogene Inc.'s principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.

What is Neurogene Inc.'s Standard Industrial Classification (SIC) code?

Neurogene Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-05-10 07:31:29

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On May 10, 2024, Neurogene Inc. (the "Company") issued a press release announcing financial results for the quarter ended March 31, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on May 10, 2024, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 2.02 and Exhibits 99.1 and 99.2 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibits 99.1 and 99.2 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated May 10, 2024 99.2 Corporate Presentation (May 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: May 10, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing